Logo image of LYEL

LYELL IMMUNOPHARMA INC (LYEL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LYEL - US55083R2031 - Common Stock

34.46 USD
+1.05 (+3.14%)
Last: 12/12/2025, 8:00:00 PM
34 USD
-0.46 (-1.33%)
After Hours: 12/12/2025, 8:00:00 PM
Fundamental Rating

3

Overall LYEL gets a fundamental rating of 3 out of 10. We evaluated LYEL against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for LYEL as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, LYEL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LYEL had negative earnings in the past year.
LYEL had a negative operating cash flow in the past year.
In the past 5 years LYEL always reported negative net income.
LYEL had a negative operating cash flow in each of the past 5 years.
LYEL Yearly Net Income VS EBIT VS OCF VS FCFLYEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

LYEL has a Return On Assets of -79.83%. This is in the lower half of the industry: LYEL underperforms 68.17% of its industry peers.
LYEL's Return On Equity of -98.95% is in line compared to the rest of the industry. LYEL outperforms 46.33% of its industry peers.
Industry RankSector Rank
ROA -79.83%
ROE -98.95%
ROIC N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
LYEL Yearly ROA, ROE, ROICLYEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LYEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYEL Yearly Profit, Operating, Gross MarginsLYEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

7

2. Health

2.1 Basic Checks

LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYEL has more shares outstanding than it did 1 year ago.
LYEL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LYEL Yearly Shares OutstandingLYEL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M
LYEL Yearly Total Debt VS Total AssetsLYEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.44, we must say that LYEL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LYEL (-0.44) is comparable to the rest of the industry.
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.44
ROIC/WACCN/A
WACC8.78%
LYEL Yearly LT Debt VS Equity VS FCFLYEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 10.30 indicates that LYEL has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.30, LYEL belongs to the best of the industry, outperforming 81.36% of the companies in the same industry.
A Quick Ratio of 10.30 indicates that LYEL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.30, LYEL belongs to the top of the industry, outperforming 81.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.3
Quick Ratio 10.3
LYEL Yearly Current Assets VS Current LiabilitesLYEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

LYEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.51%, which is quite impressive.
Looking at the last year, LYEL shows a very negative growth in Revenue. The Revenue has decreased by -34.92% in the last year.
Measured over the past years, LYEL shows a very negative growth in Revenue. The Revenue has been decreasing by -37.89% on average per year.
EPS 1Y (TTM)20.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.35%
Revenue 1Y (TTM)-34.92%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%-55.88%

3.2 Future

LYEL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.44% yearly.
The Revenue is expected to grow by 439.98% on average over the next years. This is a very strong growth
EPS Next Y28.6%
EPS Next 2Y18.98%
EPS Next 3Y13.44%
EPS Next 5YN/A
Revenue Next Year2.27%
Revenue Next 2Y-41.42%
Revenue Next 3Y454.46%
Revenue Next 5Y439.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LYEL Yearly Revenue VS EstimatesLYEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 20M 40M 60M 80M 100M
LYEL Yearly EPS VS EstimatesLYEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LYEL. In the last year negative earnings were reported.
Also next year LYEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYEL Price Earnings VS Forward Price EarningsLYEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYEL Per share dataLYEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

LYEL's earnings are expected to grow with 13.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.98%
EPS Next 3Y13.44%

More info and screens

0

5. Dividend

5.1 Amount

LYEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYELL IMMUNOPHARMA INC

NASDAQ:LYEL (12/12/2025, 8:00:00 PM)

After market: 34 -0.46 (-1.33%)

34.46

+1.05 (+3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners41.61%
Inst Owner Change-35.5%
Ins Owners0.57%
Ins Owner Change0.9%
Market Cap731.24M
Revenue(TTM)41.00K
Net Income(TTM)-325.66M
Analysts47.5
Price Target19.38 (-43.76%)
Short Float %1.2%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.95%
Min EPS beat(2)20.93%
Max EPS beat(2)20.98%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-15.34%
Max EPS beat(4)20.98%
EPS beat(8)6
Avg EPS beat(8)7.84%
EPS beat(12)10
Avg EPS beat(12)19.91%
EPS beat(16)13
Avg EPS beat(16)17.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)35.71%
PT rev (3m)72.73%
EPS NQ rev (1m)9.8%
EPS NQ rev (3m)15.05%
EPS NY rev (1m)3.63%
EPS NY rev (3m)31.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)114.29%
Revenue NY rev (3m)110.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17835.15
P/FCF N/A
P/OCF N/A
P/B 2.22
P/tB 2.22
EV/EBITDA N/A
EPS(TTM)-12.56
EYN/A
EPS(NY)-9.23
Fwd EYN/A
FCF(TTM)-9.28
FCFYN/A
OCF(TTM)-7.78
OCFYN/A
SpS0
BVpS15.51
TBVpS15.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.83%
ROE -98.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.92%
Cap/Sales 77722%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.3
Quick Ratio 10.3
Altman-Z -0.44
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)103.35%
Cap/Depr(5y)398.19%
Cap/Sales(3y)18080.8%
Cap/Sales(5y)11104.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.35%
EPS Next Y28.6%
EPS Next 2Y18.98%
EPS Next 3Y13.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-34.92%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%-55.88%
Revenue Next Year2.27%
Revenue Next 2Y-41.42%
Revenue Next 3Y454.46%
Revenue Next 5Y439.98%
EBIT growth 1Y7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.26%
EBIT Next 3Y-13.58%
EBIT Next 5YN/A
FCF growth 1Y-15.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.03%
OCF growth 3YN/A
OCF growth 5YN/A

LYELL IMMUNOPHARMA INC / LYEL FAQ

What is the ChartMill fundamental rating of LYELL IMMUNOPHARMA INC (LYEL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LYEL.


Can you provide the valuation status for LYELL IMMUNOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to LYELL IMMUNOPHARMA INC (LYEL). This can be considered as Overvalued.


How profitable is LYELL IMMUNOPHARMA INC (LYEL) stock?

LYELL IMMUNOPHARMA INC (LYEL) has a profitability rating of 0 / 10.


How financially healthy is LYELL IMMUNOPHARMA INC?

The financial health rating of LYELL IMMUNOPHARMA INC (LYEL) is 7 / 10.


Can you provide the expected EPS growth for LYEL stock?

The Earnings per Share (EPS) of LYELL IMMUNOPHARMA INC (LYEL) is expected to grow by 28.6% in the next year.